AI In Oncology Market Size, Share & Trends Analysis Report By Component Type (Software Solutions, Hardware), By Cancer Type (Breast Cancer, Lung Cancer), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030

AI In Oncology Market Summary

The growing initiatives undertaken by public and private organizations to invest in research and development (R&D) for the introduction of novel technologies are further anticipated to fuel market growth. For instance, in October 2022, Tempus, a company specializing in precision medicine and AI, announced a program called Tempus+. This proprietary program utilizes real-world data to power collaborative precision oncology research. A community of researchers, including Baylor College of Medicine, Allegheny Health Network, Stanford Cancer Center, Rush University Medical Center, TriHealth, and others, is already using the Tempus+ program to advance their research. Furthermore, increasing product approval of AI-associated medical devices is anticipated to boost market growth. In January 2024, the U.S. FDA approved the first AI medical device, DermaSensor, to detect skin cancer.

The future of AI applications in cancer care is poised for groundbreaking advancements, encompassing early detection, precision medicine, and personalized treatment plans. AI's ability to analyze vast datasets, identify subtle patterns, and provide real-time insights holds the potential to revolutionize cancer diagnosis and therapy, ushering in a new era of improved patient outcomes and more efficient healthcare delivery.

Survey Insights:

• The individuals who participated in the survey were writers of articles or review articles related to AI and cancer that were published between September 20, 2020, & September 20, 2022. These articles were indexed in WoS SCI-EXPANDED.

• Out of the 25,000 researchers invited to participate in the study, only 1,030 responded, resulting in a response rate of 4.12%.

• The following chart displays the fields that are most likely to benefit from AI in the next decade. Approximately one-third of respondents believe that cancer radiology would benefit the most, with pathology coming in second at 27.02%. Gynecology was considered to have the least potential for benefitting from AI, with only 1.46% of respondents selecting it. Some respondents (2.58%) mentioned that other areas not listed in the survey would benefit the most.

In pathology, which is filled with large datasets consisting of types and subtypes of disease specimens & biomarkers, it can be extremely complicated & exhausting for a human pathologist to keep up with changes. A 2022 NCBI research article studied the role of AI in early cancer diagnosis and found that it significantly improves the detection of mammographic abnormalities. AI-based systems can work continuously and can be trained to record & analyze any number of specimens. Integrating AI in pathology with large datasets of genomics & biomarkers can help ease the pathologist's role in providing an accurate and efficient diagnosis. Below is the representation of areas where AI is likely to have a clinical impact in the near future:

Market Concentration & Characteristics

Technological advancements and incorporation of AI in applications such as classification, detection, segmentation, characterization, and monitoring in cancer diagnosis are fueling market growth. Government and private investment in the field of oncology for adoption of artificial intelligence is enhancing the diagnostic and therapeutic scenario of providing efficient oncological solutions. For instance, in March 2023, Qritive launched QAi Prostate, a novel tool powered with AI for diagnosis of prostate cancer. The product helps in accurate identification of prostatic adenocarcinoma regions as well as in classifying benign and malignant tumors in biopsy tissue samples.

Various growth strategies are implemented by market players to strengthen their business revenues, further facilitating global market growth. For instance, in November 2022, Exscientia entered collaboration with The University of Texas MD Anderson Cancer Center for the advancement of novel small-molecule oncology therapies. Such collaborations and product launches are further driving the market growth.

Regulations play a crucial role in shaping the landscape of AI in the oncology industry, ensuring ethical use, patient privacy, and data security. Stringent regulatory frameworks contribute to trust and acceptance, fostering innovation while safeguarding against potential risks. Compliance with established standards enhances the credibility of AI applications, facilitating seamless integration into clinical practices and promoting responsible development in the evolving field of AI in oncology. In April 2021, the European Commission introduced the initial regulatory framework for AI within the EU. The proposal involves evaluating and categorizing AI systems capable of various applications based on the level of risk they present to users. The varying degrees of risk will determine the extent of regulatory measures applied to these AI systems.

Major players are focusing on geographical expansion to capture the untapped market. The expansion is generally done through launching facilities, or plants in new geographies or through merging or acquiring companies based in different locations. For instance, in July 2023, Lunit, a company specializing in AI-driven solutions for cancer diagnosis and treatment, is broadening its presence in the Middle East through a secured supply agreement with Seha Virtual Hospital. According to the arrangement, Lunit is set to provide its AI solution, Lunit INSIGHT MMG, for the analysis of mammography to Dr. Sulaiman Al Habib Medical Group.

Component Type Insights

Based on component type, the hardware segment led the market with the largest revenue share of 39% in 2024. Medical device manufacturers use AI technologies to innovate products to help healthcare providers enhance patient care. One of the major advantages of AI in medical devices is its capability to learn from real-world data and experience and improve its performance. Hence, several key players are investing in launching and advancing AI-based cancer therapy solutions. Moreover, governments are undertaking initiatives to promote the growth of AI-based medical devices. For instance, in January 2021, the U.S. FDA introduced an action plan for AI/ML-based Software as a Medical Device (SaMD). The plan was developed to support innovative work regulating medical devices and additional digital health technologies.

The software solutions segment is anticipated to witness at the fastest CAGR over the forecast period. The increasing adoption of AI software solutions by healthcare providers and payers operating in oncology is one of the major factors fueling software solutions segment growth. The software solutions are highly effective at predicting various types of cancer, including brain, breast, liver, lung, and prostate cancer. They offer better accuracy compared to clinicians. Hence, numerous key players are focusing on developing & launching new tools and platforms, increasing the competition in the market. For instance, in October 2023, Philips partnered with Quibim, a company specializing in imaging biomarkers, to launch AI-powered imaging and reporting solutions for Magnetic Resonance (MR) prostate screenings. In August 2023, MVision AI launched Contour+, an auto-contouring software offering standardization and shorter durations of cancer therapy.

Cancer Type Insights

Based on cancer type, the breast cancer segment led the market with the largest revenue share of 20.83% in 2024. The dominance of this segment is attributed to increasing prevalence of breast cancer among the population. According to the American Cancer Society, 316,950 new cases of invasive breast cancer are expected to be diagnosed in the U.S. in 2025. Growing cases amongst the population are propelling the need for introduction of technologically advanced products in the market, further propelling the market growth.

The prostate cancer segment is expected to register at the fastest CAGR over the forecast period. Prostate cancer generally affects 13 out of every 100 men in the U.S., according to the data published by CDC. In addition, according to the American Cancer Society, 313,780 new cases of prostate cancer are estimated to be diagnosed in the U.S. in 2025. Moreover, companies are expanding their portfolios by launching new products and services, for instance, in January 2024, Quibim expanded its AI-based prostate cancer solutions portfolio by introducing QP-Prostate, an AI-based detection tool. The tool reduces the processing time and increases accuracy & quality.

Application Insights

Based on application, the diagnostics segment led the market with the largest revenue share of 37% in 2024. Cancer diagnostics is an essential starting point for designing relevant therapeutic strategies and clinical management, and its AI-based advancement makes it more efficient and effective. Several companies are developing approaches for early diagnosis that include screening patients at risk with no symptoms & appropriately and rapidly investigating those who do. For instance, in December 2023, Dedalus S.p.A. partnered with Ibex Medical Analytics to launch an end-to-end AI-powered digital pathology solution to detect cancer.

The chemotherapy segment is expected to grow at the fastest CAGR over the forecast period. AI has the potential to predict treatment-related toxicity from radiation and chemotherapy. This capability is anticipated to guide discussions about the risks and benefits of different treatment modalities and assist in personalizing radiation therapy dose delivery.

End Use Insights

Based on end use, the hospitals segment led the market with the largest revenue share of 48.53% in 2024. This growth is attributed to the rising adoption of AI-powered solutions by hospitals, the increasing number of companies entering the market to cater to cancer care in hospitals, and positive responses from patients. The market is anticipated to grow at a significant CAGR during the forecast period. 

The surgical centers & medical institutes segment is expected to grow at the fastest CAGR over the forecast period, owing to technological advancements in the healthcare sector that have increased over recent years. Digitalizing processes and implementing AI, virtual reality, and immersive technologies are key examples that changed healthcare institutions’ diagnostic, treatment, and data collection processes, including hospitals. Furthermore, hospitals are integrating AI-powered algorithms in cancer therapy to enhance accuracy by avoiding misdiagnosis. For instance, in November 2024, IDIBAPS-Hospital Clínic Barcelona unveiled a new AI tool designed to assist in the diagnosis of prostate cancer. This tool utilizes a repository of healthcare images to improve the analysis of images associated with diagnosing, predicting, and monitoring prostate cancer.

Regional Insights

North America dominated the AI in oncology market with the largest revenue share of 43% in 2024, due to the presence of a well-developed digital infrastructure, favorable regulatory & reimbursement policies, and rising government initiatives to boost the adoption of AI technology in the healthcare industry. The rising prevalence of various cancers is propelling the need for the development of advanced therapeutics and diagnostics, which is further enabling the growth of the regional market. In November 2021, Sanofi entered into a collaboration with Owkin Inc. and invested USD 180 million in Owkin’s AI for the advancement of the oncology pipeline.

U.S. AI in Oncology Market Trends

The AI in oncology market in the U.S. accounted for the largest revenue share in the North America in 2024. The market is experiencing significant growth owing to the surging demand for AI applications to revolutionize medicine and advance research, diagnostics, & cancer treatment. For instance, in April 2025, Risa Labs secured USD 3.5 million in funding to enhance cancer treatment through an AI operating system. 

Moreover, increasing FDA initiatives significantly contribute to the growth of the U.S. AI in oncology industry. For instance, the FDA's efforts, as highlighted in a December 2023 factsheet, have led to the authorization, clearance, or approval of over 690 AI-enabled devices.

The Canada AI in oncology market is anticipated to grow at a significant CAGR of 26.8% during the forecast period, due to rising cancer cases in the country. Furthermore, AI is rapidly reshaping Canadian healthcare, particularly in oncology, with government support and funding driving significant advancements. The Canadian Cancer Society (CCS) actively backs AI applications, funding research teams focused on early detection and cancer care innovations. For instance, the CCS funded four research teams in December 2023 to innovate early detection, cancer prevention, and care using AI. In addition, in January 2025, AstraZeneca announced an investment of USD 820 million to expand its global research and development hub in Ontario. This investment aims to enhance the company's R&D capabilities and improve clinical trial design by utilizing artificial intelligence and digital health technologies in oncology, immunology, and infectious diseases.

“AstraZeneca’s continued investment in Ontario is crucial to advancing innovative medicines that treat, prevent, and may one day cure complex diseases like prostate, lung, and breast cancer, as well as rare diseases.”

-Gaby Bourbara, President of AstraZeneca Canada

Asia Pacific AI in Oncology Market Trends

The AI in oncology market in Asia Pacific is expected to grow at the fastest CAGR over the projected period. The growth is attributed to the rising adoption of digitalization in diagnostic laboratories and hospitals, aided by a growing geriatric population and an increasing prevalence of cancer among the population. For instance, according to GLOBOCAN in 2022, there were an estimated 19.9 million new cancer cases worldwide, with Asia-Pacific accounting for 9.8 million. Furthermore, key players are taking initiatives to improve cancer care in the region. In June 2022, GE Healthcare collaborated with the National Cancer Centre Singapore with an aim to focus on artificial intelligence to improve cancer care.

The China AI in oncology market accounted for the largest market revenue share of 22.75% in Asia Pacific in 2024. Ongoing research initiatives leverage advancements in ML, image analysis, and data processing to enhance the accuracy & efficiency of AI applications in oncology. For instance, in April 2025, Hong Kong-based researchers developed a thyroid cancer AI assistant to diagnose and classify thyroid cancer stages and risks. Such developments are expected to enhance diagnostic efficiency and improve patient management.

The AI in oncology market in India is primarily driven by various factors such as the increasing prevalence of cancer, the growing need for advanced diagnostic & treatment solutions, and the rising adoption of AI technologies in healthcare for improved patient outcomes. According to GLOBOCAN 2022, more than 1.4 million new cancer cases were diagnosed in India in 2022. Moreover, advancements in healthcare infrastructure and digitalization efforts support the integration of AI technologies to assist in early detection, diagnosis, and personalized cancer treatment.

The Japan AI in oncology market is anticipated to grow at a significant CAGR during the forecast period. Various factors are driving the market in Japan that include the country's commitment to maximizing the positive impact of AI on society rather than imposing strict regulations due to perceived risks. Moreover, collaborations and product launches between technology companies and hospitals are key drivers of market growth in Japan. For instance, in August 2023, BostonGene, NEC Corporation, and Japan Industrial Partners collaborated to establish BostonGene Japan, Inc., a joint venture based in Tokyo. 

Key AI In Oncology Company Insights

Key players are adopting new product development, partnership, and merger & acquisition strategies to increase their market share. Market players such as Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, and others dominated the market. These key players have been developing novel technologies to cater to different end-use applications.

For instance, in January 2023, Massive Bio announced the plans to adopt AI use in oncology with the development and launch of drug drug-matching product in 2023. Furthermore, key participants in the industry are embracing the strategy of introducing new products to sustain a competitive advantage within the market. For instance, in January 2020, ConcertAI launched eurekaHealth 3.0, combining use-case-aligned RWD and AI technologies to develop real-world evidence services and insights for oncology clinical development.

Recent Developments

• In April 2025, scientists at the Johns Hopkins Kimmel Cancer Center developed an AI-based liquid biopsy to detect brain cancer. This technique uses machine learning technology to identify patterns of DNA fragments circulating in the blood linked to brain tumors.

• In April 2025, iCAD announced the integration of its ProFound AI Breast Health Suite into Microsoft's Precision Imaging Network, enabling cloud-hosted access for radiologists and healthcare providers. This collaboration aims to enhance mammography solutions, improve cancer detection rates, and reduce false positive results.

• In April 2025, Roche received FDA Breakthrough Device Designation for its AI-powered companion diagnostic test to identify patients with advanced non-small cell lung cancer (NSCLC).

• In April 2025, Gestalt Diagnostics, a U.S.-based startup, raised USD 7.5 million to advance AI-enabled cancer detection.

• In April 2025, South Korea-based scientists developed an advanced artificial tumor model using AI and 3D printing to study the internal environment of a cancer patient's body. This research is likely to support and enhance personalized cancer prognosis in the future.

• In April 2025, researchers at Ankara University, Turkey, developed an AI-supported mobile application that detects early-stage lung cancer through patient voice analysis.

• In April 2025, MVision AI's Contour+ received market clearance in the United Arab Emirates. This approval is expected to help MVision AI leverage its regional presence and enhance clinical radiation therapy workflows.

• In January 2024, NVIDIA Corporation partnered with Deepcell to accelerate the use of generative AI in single-cell research for stem cells, cancer, and cell therapies.

• In January 2024, MVision AI launched a comprehensive GBS™ solution for radiation therapy cancer treatment is now available for implementation in Canadian clinics.

• In January 2024, PathAI launched six more oncology indications for PathExplore, an AI-powered pathology panel used for spatial analysis of tumor microenvironment (TME).

• In December 2023, ConcertAI acquired CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO). Concurrently, ASCO has entered into a multi-year cooperation agreement with CancerLinQ. The new partnership seeks to build on CancerLinQ’s original mission, launched by ASCO in 2013, to improve cancer care and expedite clinical research. The venture will leverage real-world data, analytics, next-generation AI, and other advanced technologies to enhance and expand CancerLinQ’s capabilities.

• In November 2023, GE Healthcare launched MyBreastAI suite, a platform that integrates three AI applications from software developed by iCAD to help with breast cancer detection and workflows.

• In November 2022, Azra AI partnered with Massive Bio to improve cancer clinical care through early identification and targeted treatment options for patients. 

AI In Oncology Market Report Scope

Global AI in Oncology Market Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global AI in oncology market report based on component, cancer type, application, end use, and region:

• Component Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Software Solutions

  • Hardware

  • Services

• Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Breast Cancer

  • Lung Cancer

  • Prostate Cancer

  • Colorectal Cancer

  • Brain Tumor

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnostics (Pathology, Cancer Radiology)

  • Radiation therapy (Radiotherapy)

  • Research & Development (Drug design, development process, etc.)

  • Chemotherapy

  • Immunotherapy

• End Use Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Surgical Centers & Medical Institutes

  • Others (Pharmaceutical companies, Research institutes & training centers)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait